期刊文献+

血液保存液在连续性血液滤过中的应用

Application of acid citrate dextrose in contiunous veno-venous hemofiltration
原文传递
导出
摘要 目的评价血液保存液用于连续性血液滤过(CVVH)治疗的效果和安全性。方法77例有出血倾向的重症患者行CVVH治疗,分为局部肝素抗凝组(A组,31例)和局部枸橼酸葡萄糖(ACD)抗凝组(B组,46例)。B组用ACD作抗凝剂,维持滤器后离子钙(iCa2+)0.25-0.35mmol/L。比较两组滤器的寿命、抗凝效果和不良反应,并进行经济学评价。结果 A组滤器使用寿命短于B组[(17.3±1.4)h vs.(41.5±4.6)h](P<0.01)。两组治疗前后凝血酶原时间、活化部分凝血酶时间无明显变化;但A组治疗后血小板水平明显下降[(130.50±58.20)×109/L vs.(111.10±45.40)×109/L](P<0.01)。B组平均输血量、每日治疗成本明显少于A组[(7.4±2.3)ml/h vs.(23.4±4.8)ml/h、(3371±249)元vs.(4334±1107)元](P<0.05或P<0.01)。B组有13例次并发代谢性碱中毒,降低置换液中碳酸氢钠至28mmol/L后碱中毒获纠正。结论 CVVH治疗中,ACD抗凝方案安全、有效、经济,易于临床推广。调整置换液碳酸氢钠浓度可有效避免代谢性碱中毒的发生。 Objective To assess the effectiveness and safety of acid citrate dextrose (ACD) solution in contiunous veno-venous hemofiltration(CVVH). Methods A total of 77 patients with bleeding risk was divided into two groups of A(treated with regional heparin anticoagulation, 31 cases) and B(treated with regional ACD anticoagulation, 46 cases). ACD was taken as anticoagulant to maintenance post-filter ionized calcium(iCa2+) 0. 25-0. 35 mmol/L. The dialyzer lifespan, anticoagulation effectiveness,adverse effects and costs were compared. Results The mean dialyzer lifespan in group A was shorter than that in group B[(17. 3±1. 4) h vs. (41.5±4. 6) hi (P〈0. 01). Compared with before, the prothrombin time and activated partial thromboplastin time were not obvioulsy changed after treatment in groups of A and B, but platelet count was decreased in group A[ (130.50±58. 20) )×10^9/L vs. (111.10±45.40)×10^9/L](P〈0. 01). The amount of blood transfusion and cost in group B were less than those in group At(7. 4±2.3) ml/h vs. (23.4±4. 8) ml/h and (3371±249) RMB vs. (4334±1107) RMB] (P〈0. 05 or P〈0. 01). The metabolic alkalosis occurred in 13 cases of group B, which was corrected by decreasing the concentration of sodium bicarbonate to 28 mmol/L in the hemofiltration solution. Conclusion ACD anticoagulation in CVVH treatment is safe, effective, cheap and easy for clinical application. Metabolic alkalosis can be prevented by adjusting the concentration of sodium bicarbonate in replacement solution.
出处 《江苏医药》 CAS 北大核心 2013年第7期799-801,共3页 Jiangsu Medical Journal
基金 苏州市科技发展计划指导项目(SYSD2011088)
关键词 连续性血液滤过 局部抗凝 Contiunous veno-venous hemofiltration Regional anticoagulation
  • 相关文献

参考文献9

  • 1Kutsogiannis DJ, Gibney RT, Stollery D, et al. Regionalcitrate versus systemic heparin anticoagulation for continuousrenal replacement in critically ill patients [J]. Kidney Int,2005,67(6):2361-2367.
  • 2Oudemans-van Straaten HM,Bosman RJ,Koopmans M, et al.Citrate anticoagulation for continuous venovenous hemofiltra-tion[J]. Crit Care Med,2009,37(2) :545-552.
  • 3季大玺,龚德华,谢红浪,徐斌,刘芸,黎磊石.枸橼酸抗凝在连续性静脉-静脉血液滤过中的应用[J].肾脏病与透析肾移植杂志,2002,11(2):101-105. 被引量:78
  • 4桂保松,吕星,高卫华,王亮琪,郭蕊军,姚钢炼.新型枸橼酸盐浓缩抗凝血液透析液的实验研究[J].中国血液净化,2002,1(3):36-41. 被引量:13
  • 5舒同,曾龙驿,穆攀伟,王曼曼,张国超,陈燕铭.持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析[J].中华流行病学杂志,2009,30(7):737-739. 被引量:12
  • 6Davenport A. Replacement and dialysate fluids for patientswith acute renal failure treated by continuous veno-venoushaemofiltration and/or haemodiafiltration [J]. Contrib Nephrol,2004,144:317-328.,.
  • 7Oudemans-van Straaten HM. Citrate anticoagulation forcontinuous renal replacement therapy in_ the critically ill[J].Blood Purif,2010,29(2):19M96.
  • 8Gabutti L,Marone C,Colucci G,et al. Citrate anticoagulationin continuous venovenous hemodiafiltration : a metab^ipchallenge[J], Intensive Care Med,2002,28(10) : 1419-1425.
  • 9Fealy N, Baldwin I,Johnstone M, et al. A pilot randomizedcontrolled crossover study comparing regional heparinizationto regional citrate anticoagulation for continuous venovenoushemofiltration[J]. Int J Artif Organs,2007,30(4) :301-307.

二级参考文献16

  • 1金文胜,潘长玉.代谢综合征——促进心血管疾病流行的祸首[J].中华内分泌代谢杂志,2005,21(4):413-414. 被引量:15
  • 2邹大进,杨前勇.糖尿病的诊治与进展——糖尿病与临床各科的关系[J].药学服务与研究,2006,6(1):1-5. 被引量:21
  • 3WHO Consultation Group.Definition,diagnosis and classification of diabetes mellitus and its complications.2nd.Part 1:Diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99.Genena:World Health Organisation,1999:1-59.
  • 4中华人民共和国卫生部.新药临床研究指导原则.第1辑.1993:82-85.
  • 5[1]Peter H, Katrin I, Oliver T, et al. Acid- base balance and substitution fluid during continuous hemofiltration. Kidney Int, 1999, 56(suppl 72): S37 - S40
  • 6[2]Kunstle T, Maulhardt S, Grunberger M, et al. Heparin - induced thrombocytopenia and hemofiltration: regional anticoagulation with sodium citrate. Anasthesiol Intensivmed Notfallmed Schmerzther,2000, 35(2): 115 - 118
  • 7[3]Sramek V, Novak I, Matejovic M, et al. Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. Intensive Care Med, 1998, 24(3): 262 - 264
  • 8[4]Kutsogiannis DJ, Mayers I, Chin WD, et al. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis, 2000, 35(5): 802 -811
  • 9[5]Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int, 1999, 56(6): 2005-2015
  • 10[6]Martien J. F. M, Jeroen K. D, Theodoor H. K, et al. Citrate compared to low molecular weight hepatin anticoagulation in chronic hemodialysis patients. Kidney Int, 1996, 49: 806- 813

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部